Roivant Sciences (ROIV) Stock Analysis
This is a peer-relative look at Roivant Sciences (ROIV): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.
Company Profile
| Profile Item | ROIV |
|---|---|
| Name | Roivant Sciences Ltd. |
| Country/Region | United Kingdom |
| GICS Sector | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology |
| GICS Sub-Industry | Biotechnology |
| Market Capitalization | 28.08 billion USD |
| Currency | USD |
| Exchange | Nasdaq |
| Listing Date | December 8, 2020 |
| Security Type | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | Current stock: ROIV | Industry group median |
|---|---|---|
| Total Return (1Y) | 96.75% | 24.62% |
| Total Return (3Y, Annualized) | 68.04% | 20.37% |
| Total Return (5Y, Annualized) | 36.73% | -4.02% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | Current stock: ROIV | Industry group median |
|---|---|---|
| Volatility (1Y, Annualized) | 47.99% | 66.36% |
| Beta (5Y) | 1.17 | 0.93 |
| Max Drawdown (5Y) | -79.22% | -80.19% |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | Current stock: ROIV | Industry group median |
|---|---|---|
| Sharpe Ratio (1Y) | 1.93 | 0.36 |
| Sortino Ratio (1Y) | 4.03 | 0.58 |
Profitability
ROE (TTM)
Roivant Sciences (ROIV) has negative ROE of -8.52%. That can come from trailing losses or negative book equity, so it is a warning state rather than a clean capital-efficiency measure.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-8.52%
Group distribution
- Max
- 109.18%
- Q3
- 6.23%
- ROIV
- -8.52%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Largest peers
- LLY
- 86.02%
- NVS
- 24.33%
- AZN
- 22.57%
- JNJ
- 20.02%
- MRK
- 5.06%
- ROIV
- -8.52%
- ABBV
- --
Net Margin (TTM)
Roivant Sciences (ROIV) keeps 0.00% of revenue as net profit, roughly in line with the peer group’s normal net margin range. Its full cost stack is taking a typical share of sales for the industry.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- Max
- 18.05%
- Q3
- 4.78%
- ROIV
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Largest peers
- LLY
- 31.90%
- AZN
- 17.68%
- NVS
- 17.49%
- JNJ
- 16.20%
- ABBV
- 15.67%
- MRK
- 3.64%
- ROIV
- 0.00%
Operating Margin (TTM)
Roivant Sciences (ROIV) has negative operating margin of -25,408.11%. Core operations were loss-making before interest and taxes over the trailing period.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-25,408.11%
Group distribution
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- ROIV
- -25,408.11%
Largest peers
- LLY
- 53.66%
- ABBV
- 39.59%
- MRK
- 35.22%
- NVS
- 34.27%
- AZN
- 29.57%
- JNJ
- 25.74%
- ROIV
- -25,408.11%
Profitability Metrics
| Metric | Current stock: ROIV | Industry group median |
|---|---|---|
| ROE (TTM) | -8.52% | -26.66% |
| ROA (TTM) | -16.28% | -12.50% |
| Net Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | -25,408.11% | 0.00% |
| Gross Margin (TTM) | 0.00% | 37.87% |
Growth
Revenue Growth
Roivant Sciences (ROIV) grew revenue -71.57%, in the lower peer quartile. The top line is expanding more slowly than at most peers, which can reflect softer demand, lost share, or weaker pricing.
EPS Growth
No usable EPS growth is available for Roivant Sciences (ROIV) this period, so the earnings-momentum read is skipped.
Growth Metrics
| Metric | Current stock: ROIV | Industry group median |
|---|---|---|
| Revenue Growth (YoY) | -71.57% | 11.45% |
| Revenue Growth (3Y CAGR) | -36.01% | 9.94% |
| EPS Growth (YoY) | -- | 4.28% |
| EPS Growth (3Y CAGR) | -- | 4.17% |
Financial Strength
Current Ratio (MRQ)
Roivant Sciences (ROIV) has current ratio of 16.72, above the industry’s typical middle range. Liquidity looks ample versus peers, though an unusually high cushion can also mean idle current assets or inefficient working capital.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.72
Group distribution
- Max
- 25.13
- ROIV
- 16.72
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Largest peers
- ROIV
- 16.72
- LLY
- 1.39
- MRK
- 1.35
- JNJ
- 1.02
- AZN
- 1.01
- NVS
- 0.88
- ABBV
- 0.87
Debt / Equity (MRQ)
Roivant Sciences (ROIV) has debt-to-equity ratio of 0.02, roughly in line with the peer group’s normal leverage range. Its mix of debt and equity looks typical for the industry.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.02
Group distribution
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- ROIV
- 0.02
- Q1
- 0.02
- Min
- 0.00
Largest peers
- NVS
- 1.29
- LLY
- 1.23
- MRK
- 1.20
- AZN
- 0.66
- JNJ
- 0.55
- ROIV
- 0.02
- ABBV
- --
Financial Strength Metrics
| Metric | Current stock: ROIV | Industry group median |
|---|---|---|
| Current Ratio (MRQ) | 16.72 | 5.52 |
| Debt / Equity (MRQ) | 0.02 | 0.15 |
| Net Debt / EBITDA | -- | 1.08 |
Dividends
Dividend Yield (TTM)
Roivant Sciences (ROIV) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- ROIV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- NVS
- 2.88%
- ABBV
- 2.40%
- MRK
- 2.29%
- JNJ
- 1.94%
- AZN
- 1.73%
- LLY
- 0.49%
- ROIV
- 0.00%
Dividend Payout Ratio (TTM)
Roivant Sciences (ROIV) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- ROIV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- MRK
- 343.43%
- ABBV
- 117.35%
- NVS
- 90.46%
- JNJ
- 80.12%
- AZN
- 45.38%
- LLY
- 21.71%
- ROIV
- 0.00%
Dividend Metrics
| Metric | Current stock: ROIV | Industry group median |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
No usable P/E ratio is available for Roivant Sciences (ROIV) this period, so the trailing-earnings valuation read is skipped.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
Group distribution
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ROIV
- --
Largest peers
- MRK
- 148.21
- ABBV
- 50.05
- LLY
- 43.95
- JNJ
- 41.92
- NVS
- 31.02
- AZN
- 26.37
- ROIV
- --
P/S Ratio (TTM)
Roivant Sciences (ROIV) trades at 3,728.61 on P/S ratio, above the industry benchmark range. The stock is being valued at an unusually rich price per dollar of trailing revenue.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
3,728.61
Group distribution
- ROIV
- 3,728.61
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
Largest peers
- ROIV
- 3,728.61
- LLY
- 13.95
- ABBV
- 7.80
- JNJ
- 6.69
- MRK
- 5.37
- NVS
- 5.35
- AZN
- 4.63
P/B Ratio (MRQ)
Roivant Sciences (ROIV) trades at 6.64 on P/B ratio, in the higher book-value quartile. The market is paying a premium to book, so stronger ROE, cleaner assets, or a better growth profile need to justify it.
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64
Group distribution
- Max
- 13.53
- ROIV
- 6.64
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Largest peers
- LLY
- 29.96
- NVS
- 8.25
- JNJ
- 8.16
- MRK
- 8.06
- ROIV
- 6.64
- AZN
- 5.59
- ABBV
- -112.34
Valuation Metrics
| Metric | Current stock: ROIV | Industry group median |
|---|---|---|
| P/E Ratio (TTM) | -- | 26.69 |
| P/S Ratio (TTM) | 3,728.61 | 7.30 |
| P/B Ratio (MRQ) | 6.64 | 3.25 |
| Free Cash Flow Yield (TTM) | -3.98% | -1.66% |